The names, and why there are so many

Families hear several names for the same condition, often from different doctors in the same building. Here is what each one means.

CNO

Chronic Nonbacterial Osteomyelitis. The broad term, and the one most specialists now prefer, because it covers the whole spectrum including children with a single lesion that never recurs.

CRMO

Chronic Recurrent Multifocal Osteomyelitis. The older and still widely used name. It describes the classic presentation, multiple lesions that flare and settle, but not every patient is multifocal or recurrent.

CNO in adults

An international expert panel in 2025 recommended that adults with sterile bone inflammation all be called chronic non-bacterial osteitis, retiring the separate adult labels.

SAPHO

Synovitis, Acne, Pustulosis, Hyperostosis, Osteitis. Shares features with CNO and was once treated as the adult version of it. The 2025 adult consensus folds it into the same CNO framework rather than keeping it as a separate disease.

In practice CNO and CRMO are used interchangeably. If your child's chart says one and your rheumatologist says the other, nothing has changed about the diagnosis.

Autoinflammatory, not autoimmune

This distinction gets corrected often in family groups and it is worth getting right. In an autoimmune disease, the adaptive immune system produces antibodies that attack the body's own tissue. CNO is autoinflammatory: the innate immune system, the older and less targeted half of immunity, is switched on when it should be quiet. There is no autoantibody to test for, which is part of why diagnosis takes so long.

The inflammation in bone also drives osteoclasts, the cells that break bone down. That is why untreated CNO can cause real structural damage and not just pain, and it is the reason bone-directed drugs like bisphosphonates work at all.

How common it is

Incidence figures vary widely by region and study method. Germany reports around 0.4 per 100,000, the UK and Ireland around 0.65, and the northwest United States around 2.3. At some centers CNO is diagnosed about as often as bacterial bone infection, which suggests the true number is higher than the lower estimates.

Where it shows up

Lesions most often appear in the metaphyses of long bones, near the growth plates, and in the clavicle, pelvis, spine, jaw, and feet. Clavicle and jaw lesions are fairly characteristic of CNO and less common in other conditions. Many children have lesions on imaging that are causing no symptoms at all, and some have severe pain in an area where imaging shows little.

What it feels like

Bone pain is the defining symptom and it is usually intermittent, often worse at night, and focal rather than all over. Beyond that, the things families consistently report:

• Fatigue when the disease is active. This is real, it is part of the illness rather than a reaction to it, and it is regularly underestimated by everyone except the child. It affects school more than the pain does for some children.
• Joint swelling, since CNO can involve joints as well as bone.
• Skin, eye, or digestive symptoms, reflecting the conditions CNO travels with.
• Limping or a change in how a child moves, sometimes before they complain of anything.
• Symptoms that fluctuate over years. Good months and bad months are the pattern, not a sign that something changed.

Fatigue is worth naming specifically when you talk to a school, because it is invisible and it does not look like pain. A child who is keeping up academically but sleeping every afternoon is still significantly affected.

What CNO is not

• Not an infection. Cultures are negative. Antibiotics do not treat it, though many children get a course of them before the diagnosis is made.
• Not cancer, though the imaging can look worrying enough that a biopsy is done to be sure.
• Not growing pains. Growing pains are bilateral, evening only, and resolve by morning. CNO pain is usually focal, often worse at night but persistent, and does not resolve on its own over weeks.
• Not caused by anything a parent did. There is no diet, injury, vaccine, or exposure known to cause CNO.

The long view

Many children reach sustained remission and return to full activity. Some have a course that continues for years or into adulthood. Treatment options today are meaningfully better than they were a decade ago, and the research pipeline is active. What predicts a good outcome most reliably is getting treatment matched to the disease early, particularly when the spine is involved.

How the diagnosis gets made

A pediatric rheumatologist puts together the pattern of bone pain, the appearance and distribution of lesions on MRI, blood work, and the absence of infection or malignancy. Several formal criteria sets exist, including the Jansson and Bristol criteria.

Median time to diagnosis is commonly reported at around 15 months, and plenty of families describe two years or more of being told it was growing pains, a sports injury, or an infection. That delay is a feature of the disease being rare and having no defining blood test, not a failure on your part.

Whole-body MRI and dedicated MRI are different tools

This comes up constantly, and misunderstanding it leads to real problems. The two scans answer different questions.

What each test contributes

Whole-body MRI

The current standard for mapping disease at diagnosis. Active lesions show as bone marrow edema, bright on fluid-sensitive sequences such as STIR. No radiation. Often done without contrast.

Dedicated MRI

Higher detail for a single region. The right tool for the spine, for confusing pain, and for assessing whether a specific lesion is improving.

Plain X-ray

Often the first imaging done. Can show sclerosis, lysis, or hyperostosis, but is frequently normal early in the disease. A normal X-ray does not rule out CNO.

Bone biopsy

Not required to diagnose CNO, and not able to confirm it. Used to exclude tumor or infection, most importantly when there is a single lesion or the imaging looks atypical. See the section below.

ESR and CRP

Inflammatory markers. Often mildly elevated, but commonly normal even during active disease. Normal labs do not mean the disease is quiet.

Bone scan

An older approach, largely replaced by whole-body MRI, which gives better detail without radiation.

Do they always do a biopsy?

No, and this is worth understanding properly, because the answer is neither "always" nor "never" and both of those get repeated in family groups.

Biopsy is not required to diagnose CNO. Consensus recommendations state this directly. CNO remains a diagnosis built from clinical findings, labs and imaging, with other causes excluded. Around a third of the children in the EULAR/ACR validation cohort had never had a biopsy. If your child has a characteristic multifocal picture at typical sites, a biopsy may add nothing.

A biopsy cannot confirm CNO either. There is no finding that says CNO. What a biopsy shows is inflammation, sometimes fibrosis, and negative cultures. That is consistent with CNO but it is also the point: the job of the biopsy is to rule things out, not to rule CNO in.

Why the diagnosis can still be uncertain after a biopsy

This is frustrating but medically possible. A biopsy can make infection or malignancy less likely without proving that CNO is the answer. The rheumatologist still has to put the pathology together with the lesion's MRI appearance, its location, the clinical course, cultures and laboratory results, and whether other lesions are present.

This matters most with an apparently isolated lesion, such as one in the jaw. If the diagnosis stays uncertain, a useful question is whether whole-body MRI has been done, not only MRI of the painful bone. CNO lesions can be clinically silent, so finding additional ones in characteristic locations can turn an apparently unifocal presentation into a multifocal pattern and materially strengthen the diagnosis.

When consensus does call for one

Published recommendations name specific situations, and in these a biopsy is the appropriate step rather than an overreach:

• A single lesion, other than in the clavicle or mandible. This is the big one. A solitary bone lesion is the presentation that overlaps with bone tumors such as osteosarcoma and with infection, and distinguishing them matters enormously.
• Atypical imaging: abscess formation, fistula, involvement of the skull, or a diffuse pattern that does not look like CNO.
• No response to adequate second-line treatment, where the question becomes whether the original diagnosis was right.

The purpose in each case is excluding primary or secondary bone tumors and infection. Guidance also recommends the decision be made jointly across pediatric rheumatology, radiology, orthopedics or surgery, oncology and infectious disease, rather than by one clinician alone.

What can reduce the need for one

Whole-body MRI, done first. If it finds additional lesions at characteristic sites, the picture becomes typical of CNO and the argument for biopsy weakens considerably. The classification criteria reflect this: a single lesion counts against a CNO classification, while a multifocal pattern counts strongly toward it.

So the productive question is usually not "does he really need a biopsy" but "has he had a whole-body MRI yet, and what did it show?" That is the study that may answer the question without an invasive procedure, and it is reasonable to ask whether it should come first.

If a biopsy is going ahead

Ask that the microbiology be thorough. Consensus recommendations specify extended bacterial culture of at least 10 days, molecular testing for bacteria, and testing for typical and atypical mycobacteria. A short standard culture can miss a slow-growing infection, and a falsely negative result sends everyone down the CNO path with an infection still untreated. This is a specific, reasonable thing to request.

• What exactly are you trying to rule out with this biopsy?
• Has he had whole-body imaging, and would that change whether we need it?
• Is this a single lesion, and is it in a site where biopsy is usually recommended?
• Who is involved in this decision besides rheumatology?
• What cultures and molecular tests will be sent, and for how long will they be held?
• What happens if the result is inflammation with negative cultures, which is the expected CNO result?

Preparing for an MRI

A whole-body MRI is a long scan, commonly 45 to 90 minutes, and the child has to stay still for it. This is the part of CNO care families ask about most and get told about least.

Sedation or awake

Younger children, roughly under six or seven, usually need sedation or general anesthesia. Older children often manage awake, especially with preparation. Ask which is planned, because sedation means fasting instructions and a longer day.

Child life specialists

Most pediatric centers have them, and they are the single most useful resource here. They offer mock scanners, practice sessions, and distraction techniques that let many children avoid sedation entirely. Ask for one rather than waiting to be offered.

Noise and comfort

MRI scanners are loud. Earplugs or headphones are standard, and many centers can play music or a movie. Ask what is available at yours, and bring a comfort item.

Contrast

CNO lesions are usually identified on non-contrast fluid-sensitive sequences, so contrast is not always needed. Worth asking whether it is planned and why, particularly if an IV is a significant stressor for your child.

Practical setup

No metal, comfortable clothing without zips or snaps if the center allows own clothes, and feet-first positioning where possible if your child is anxious in enclosed spaces.

Afterwards

Ask when results will be available, how you will get them, and request a copy of the written report rather than only a verbal summary. Those reports accumulate into the record that supports insurance appeals and second opinions.

Who is on the team

A pediatric rheumatologist coordinates care and is the person who makes the treatment decisions. Depending on how your child presents, others get drawn in:

Pediatric radiologist

Ideally one who reads CNO imaging regularly, since the patterns are distinctive and easy to misread as infection or tumor by someone who rarely sees them.

Orthopedics

For structural complications: pathological fracture, vertebral collapse, limb length differences, deformity.

Gastroenterology

CNO is associated with inflammatory bowel disease. New or persistent gut symptoms get referred here, and a coexisting diagnosis changes which drug is chosen.

Dermatology

For the psoriasis and other skin conditions that travel with CNO, and for the paradoxical psoriasis that TNF inhibitors can trigger.

Ophthalmology

Less commonly needed, but CNO can involve eye inflammation. Report new eye redness, pain, or vision change promptly rather than waiting, since eye inflammation can be quiet and still be doing damage.

Pain management and pain psychology

For pain that persists beyond what disease control explains, and for the skills side of living with a body that hurts. See managing pain.

Dentistry and orthodontics

For jaw lesions, and required before starting a bone-directed drug.

Infectious disease

Usually involved early, to confirm infection has been properly excluded rather than to treat anything.

Dedicated CNO programs exist at a small number of centers and run this as a single multidisciplinary clinic rather than as a series of separate referrals you chase yourself. If you are coordinating all of this alone, that is a reason to ask about a second opinion at such a center.

Questions worth asking at the first visits

• How many CNO patients do you currently treat?
• How many lesions did imaging show, and exactly where are they?
• Is there any spinal involvement, and how will we monitor it?
• Is any lesion near a growth plate, and what does that mean for growth?
• What is the treatment plan, and what would make us change it?
• What symptoms should make me call you rather than wait for the next visit?
• What activity is safe right now, and what is not?
• Are there registries or clinical trials we should join?
• How often will we scan, and what are we looking for each time?
• How will you measure whether the disease is active, and is there anything you want me tracking between visits?

Second opinions

Expertise in CNO is concentrated at a relatively small number of pediatric centers. A second opinion from a rheumatologist who sees CNO regularly is reasonable in almost any case, and is worth pursuing if the diagnosis was made outside a major pediatric center, if treatment is not working, or if there is spinal involvement. Asking for one is not a criticism of your current doctor and most are used to it.

Is it genetic?

For the large majority of patients, no single gene explains it. CNO has a complex genetic background involving the IL-1 pathway among others, and it is not inherited in a simple pattern. Siblings carry a somewhat elevated risk but the absolute risk stays low. Mention it to your rheumatologist if a sibling develops unexplained bone pain.

A small minority of cases are caused by identified single-gene variants. These usually present differently, often much earlier or with other organ involvement, and identifying them can change treatment.

Most families will never need this table. It is here for the ones who have been told genetic testing is relevant to their child.

What genetic testing can and cannot tell you

Some children are offered a broad primary immunodeficiency or autoinflammatory gene panel. This is more likely when the presentation is unusually early, includes recurrent or unexplained high fevers, unusual infections, significant skin or gastrointestinal disease, a strong family history, or other features that make the team wonder whether a rare single-gene inflammatory disorder could be producing a CNO-like picture.

These panels can include hundreds of genes. They are not a test for a single "CRMO gene," because no such diagnostic gene exists for typical CNO. Their value is in looking for a different or overlapping genetic immune disorder that might help explain the presentation and, in a small number of cases, change treatment.

A negative panel does not rule out CNO and does not mean genetics play no role. Current panels only test genes and variant types that are known and technically detectable today.

A variant of uncertain significance, usually written VUS, is also not the same thing as finding the cause. It means a genetic difference was found but there is not enough evidence to know whether it causes disease. Most VUS findings should not be used by themselves to diagnose a condition or choose treatment. Ask whether the laboratory plans to reclassify the variant as new evidence becomes available, and whether a genetics consultation would add anything.

What about HLA-B27?

HLA-B27 is sometimes described in family groups as a "CRMO gene," but that is not accurate. It is a genetic marker associated most strongly with the spondyloarthritis spectrum. It may be clinically relevant when a child with CNO also has sacroiliitis, enthesitis, inflammatory arthritis, or other features suggesting juvenile spondyloarthritis or an overlap phenotype.

Being HLA-B27 positive does not diagnose CNO, and being negative does not rule it out.

Conditions that get involved

CNO travels with other inflammatory conditions often enough that your team will watch for them: inflammatory bowel disease, psoriasis, inflammatory arthritis, and less commonly eye inflammation. Report new gut symptoms, skin changes, joint swelling, or eye redness and pain. These associations also shape treatment, since a drug that treats both conditions is usually preferred.

Involvement outside the bones

CNO is a bone disease but it does not always stay there. Recent work identifying distinct clinical clusters in both children and adults found that extraosseous involvement, meaning disease outside the skeleton, marks a more severe course and is associated with needing biologic treatment sooner.

Pulmonary involvement in particular has been flagged as a marker of greater severity. This is worth knowing because breathing symptoms in a child with CNO are easy to attribute to something else, and because chest pain and difficulty taking a deep breath are also classic symptoms of thoracic spine lesions. The two are different problems with different workups, and neither is a reason to dismiss the other.

Practically: report persistent cough, shortness of breath, or chest symptoms to the rheumatology team rather than only to a pediatrician, so they are interpreted in the context of the CNO rather than as an unrelated respiratory issue.

Jaw involvement

Mandibular lesions are one of the more characteristic sites in CNO and they bring specific concerns: jaw pain, swelling, difficulty chewing or opening the mouth, and dental problems. Tell your dentist about the diagnosis, and tell the rheumatology team about jaw symptoms.

The connection that catches families out is bisphosphonates, and it runs in both directions.

They are used to treat jaw lesions, not merely tolerated despite them. In a case series of patients with CNO of the jaw treated with zoledronic acid, average pain scores fell from about 7.7 to 2.5 out of 10, with roughly 84 percent reporting partial or complete relief. Worth knowing alongside that: about two thirds had pain return, usually within the first year, so a repeat course is common rather than a sign of failure. Imaging and pain did not track together reliably, which is the same pattern as everywhere else in this disease.

The osteonecrosis concern is real but small, and it is mostly about dental procedures. Osteonecrosis of the jaw is a known risk of bone-directed drugs, and it is rare in children. The jaw CNO series above reported none from zoledronic acid. What remains standard is a dental check before starting, and scheduling extractions or oral surgery around treatment rather than during it. Tell the dentist your child is on or starting a bisphosphonate before any procedure, and tell the rheumatology team about jaw symptoms.

Why it is treated differently

More than a quarter of CNO patients develop vertebral lesions, most often in the thoracic spine. Unlike a lesion in a tibia, a vertebral lesion can lead to loss of vertebral body height, compression fracture, kyphosis, or scoliosis. Nearly half of patients with vertebral involvement show some vertebral height loss. That damage does not reverse.

For this reason, spinal involvement is one of the two situations where consensus guidance says to escalate past NSAIDs rather than wait and see. The other is failing to improve on NSAIDs.

Silent lesions are the norm

Vertebral lesions frequently cause no symptoms at all. A child can have a lesion at C2 or T10, feel nothing, and only learn about it from a scan. This is precisely why whole-body MRI is recommended at diagnosis: the point is to find the spine lesions that are not announcing themselves.

The reverse also happens, and it is the situation that frustrates families most. A child has significant spinal pain, the whole-body MRI shows nothing in the spine, and the pain gets attributed to something else. A screening scan is lower resolution than a dedicated one, and lesions change over time. A dedicated spine MRI is the appropriate next question there.

Symptoms families report

Thoracic spine involvement in particular produces descriptions that do not sound like back pain at first:

• Chest pain, or pain wrapping around the ribs
• Feeling unable to take a deep breath, or that the chest is being crushed or compressed
• Pain that is worse lying down or at night
• Reluctance to bend, twist, or be lifted under the arms
• In younger children, a change in posture or how they carry themselves rather than a complaint

Cardiac and pulmonary workups for chest pain in these children often come back clean, which is reassuring but does not explain the symptom. If the workup is negative and the child has known CNO, spinal imaging is a reasonable next step to raise with the rheumatology team.

How spinal disease is monitored

Expect repeat imaging on a defined schedule rather than only when something hurts. Consensus recommendations put follow-up imaging at roughly every 6 to 12 months depending on the course, with clinical assessment every 3 to 6 months. With known vertebral involvement, your team may image the spine more often and may use dedicated spine sequences rather than relying on the whole-body scan alone. Ask what the schedule is and what a change on the next scan would mean for treatment.

Activity with spinal involvement

Restrictions are individual and depend on which vertebrae are involved, whether there is height loss, and how active the disease is. Contact sports, gymnastics, diving, trampolines, and heavy backpacks are the usual conversations. Get the answer from your rheumatologist rather than from general advice, and get it in writing if the school needs it.

The treatment ladder

Treatment escalates based on where the lesions are, how severe the disease is, whether the spine is involved, and how the child responds. Approaches vary between centers, and reasonable rheumatologists make different calls.

"My child already takes ibuprofen. Is that the same thing?"

Ibuprofen is an NSAID. The important distinction is not weak versus strong. It is the drug, the dose, how long it acts, and whether it is being taken on a regular anti-inflammatory schedule or only occasionally for pain.

A child taking ibuprofen as needed after a painful day is not necessarily getting the same treatment strategy as a child prescribed scheduled naproxen or once-daily meloxicam for continuous coverage. Do not add or combine NSAIDs on your own. Ibuprofen, naproxen, meloxicam and similar drugs generally should not be taken together unless the treating clinician specifically directs it.

Does a child with spinal disease have to fail NSAIDs first?

Not necessarily, and this is an important exception to the usual sequence. Active vertebral disease, especially with compression, fracture, height loss or other structural damage, can justify moving quickly to a bisphosphonate or a TNF inhibitor rather than waiting out a prolonged NSAID trial. An NSAID may still be used alongside the escalated treatment.

In other words, NSAIDs and bisphosphonates are not always an either/or decision. With high-risk spinal disease, the bone-directed treatment is addressing a risk that pain control and NSAIDs alone cannot adequately cover.

Bisphosphonate or TNF inhibitor?

This is the most common fork in the road, and there is no head-to-head trial answering it. Both achieve clinical remission at around six months and radiologic improvement at around twelve in retrospective studies. The considerations that usually decide it:

Corticosteroids

Short courses of prednisone, generally up to about six weeks, are used to settle a bad flare. They are not a long-term strategy in CNO because of the side effect burden in growing children, and consensus guidance specifically avoids them where there is structural spinal damage.

How long treatment lasts

Months to years is the honest answer, with one to two years being a common range quoted by dedicated CNO programs. Disease can recur after medication stops, but there is no single evidence-based rule for how every CNO medication should be withdrawn. Some drugs, particularly corticosteroids and certain pain medicines, require tapering for pharmacologic reasons. Biologics and conventional DMARDs may be spaced out, tapered, or simply stopped, depending on the drug, the center, how long remission has lasted, the imaging, and the child's history. German consensus recommendations suggest following patients for a minimum of three years after medication-free remission is reached. Ask your team what their criteria are for stopping, and whether they require imaging remission as well as clinical remission.

How solid is the evidence behind all this

Thinner than most families assume, and it is better to know that than to discover it during a disagreement with a doctor.

A systematic review of treatment in pediatric CNO found no randomized controlled trials at all. The evidence base is 31 cohort studies and 22 case series, rated overall as low quality, with wide variation in how outcomes were even measured. Reported response rates swing accordingly: methotrexate anywhere from 16 to 66 percent across studies, TNF inhibitors from 20 to 91 percent. One small placebo-controlled pilot trial of pamidronate exists, and that is close to the whole of the randomized evidence.

What follows from that is not that treatment is guesswork. Bisphosphonates and TNF inhibitors both consistently work in cohort after cohort, and consensus plans exist precisely because experienced clinicians agree on the broad approach. But it does explain why two good rheumatologists can make different calls, why centers differ, and why the field is pushing hard for actual trials. The 2025 classification criteria are part of that push, because you cannot run a trial without an agreed definition of who is in it.

Off-label prescribing

Because nothing is approved specifically for CNO, nearly every drug past NSAIDs is prescribed off label. This is normal and accepted practice in rare pediatric disease. It is also the reason prior authorization gets denied so often, and why the insurance section of this handbook exists.

What is not treatment for CNO

Families are offered a lot of things. To be clear about the evidence: there is no established role in treating CNO for gluten-free or anti-inflammatory diets, gut microbiome testing, MTHFR testing, or supplement protocols. None of that is a criticism of eating well or of a family trying to feel less powerless. If your child has a separate documented reason for a dietary change, that is a different conversation, and calcium and vitamin D are routinely recommended alongside bisphosphonates. Physical therapy, pain psychology, sleep, and gentle conditioning do have a real role and are covered under school and daily life.

What about finding the root cause?

It is completely understandable to want to know why your child developed CNO. Families may hear that a hidden root cause can be found in food, the gut microbiome, infection, environmental exposures, stress, or something else. Research into what causes and modifies CNO matters, but there is currently no single established root cause for most people with the disease.

One useful way to think about this comes from complex systems. In engineering, root-cause analysis is valuable, but complex systems do not always fail because of one defective component. Problems emerge from interactions among several contributors, feedback loops, thresholds, and conditions that are individually insufficient to cause the outcome. Human biology is an extraordinarily complex system.

For CNO it helps to separate four different ideas:

Cause

Something necessary to produce the disease.

Trigger

Something associated with the start of an episode or a change in disease activity.

Modifier

Something that makes symptoms or disease activity better or worse.

Treatment target

A biological pathway we can intervene on successfully.

Those are not interchangeable. If blocking TNF improves CNO, that tells us TNF is an important treatment target. It does not prove that too much TNF was the original cause. If a child improves after removing a particular food, the observation may be worth tracking and discussing, but improvement alone does not establish that the food caused CNO.

A more useful question: what mechanisms and contributing factors are driving my child's disease, which can we identify, and which can we safely modify?

There is nothing wrong with continuing to ask why. The distinction that matters is between investigating possible contributors and declaring an unproven factor to be the cause, particularly when doing so delays treatment of active bone inflammation.

Diet changes when a child already has a limited diet

Extra caution is warranted when a child is already a selective eater or has sensory sensitivities to taste, smell, texture or appearance. Removing gluten, dairy, corn or other broad food groups can make an already narrow diet substantially more restrictive, and can create nutritional problems during growth.

If you want to explore dietary changes anyway, especially with a child who has significant food selectivity, involving a pediatric dietitian is the safer route for protecting calories, protein, calcium, vitamin D and iron. Dietary experimentation should not substitute for treating active CNO, particularly where the spine or another structurally high-risk site is involved.

Each entry is tagged by what job it does. Treats inflammation means it acts on the disease itself. Pain only means it changes how pain is experienced without treating the lesions.

The comparison that is usually missing

Medication risks come printed on a leaflet with a list of everything ever reported. The risk of undertreated CNO does not arrive with a leaflet, so it is easy to underweight. That risk is concrete: vertebral height loss, compression fracture, kyphosis or scoliosis, growth disturbance when a lesion sits near a growth plate, and years of pain shaping a child's development and schooling. When a rheumatologist pushes to escalate treatment, this is the side of the ledger they are looking at.

None of that means every recommendation is right for your child. It means the honest question is which risk is larger here, not whether the medication has risks at all.

What gets monitored, and why

Before a first bisphosphonate infusion: the dental step

This is the one piece of preparation families most often find out about late, and it is easier to handle before treatment starts than after.

Bone-directed drugs such as pamidronate, zoledronic acid and denosumab carry a small risk of osteonecrosis of the jaw, where jaw bone fails to heal after a dental procedure. It is rare, and it is rarer still in children, but the whole point of the dental step is that the risk attaches to invasive dental work done while the drug is on board.

• Get the dental check done before the first infusion, not after it. Ask the rheumatology team to arrange or request it if nobody has raised it.
• Finish anything invasive first. Extractions, oral surgery, implants, and treating any active infection or untreated decay are better completed and healed before starting.
• Routine care carries on normally. Cleanings, checkups, fillings and X-rays are not the concern, and keeping up with them lowers the chance of needing something invasive later.
• Tell every dentist and the orthodontist. Many of these children are in or heading for braces. Bisphosphonates can slow orthodontic tooth movement, so an orthodontist planning treatment needs to know, and a new dentist will not know unless you say so.
• If a procedure becomes necessary later, have the dentist and rheumatologist talk to each other rather than either one deciding alone. It is usually about timing it between infusion cycles rather than refusing it.
• Report jaw pain or swelling, a loose tooth, exposed bone, or a dental site that is not healing.

Expected versus report it

Knowing which is which saves a lot of anxiety and a lot of unnecessary ER visits.

Expected

Flu-like aches and fever for a day or two after a first bisphosphonate infusion. Nausea and fatigue the day after methotrexate. Stinging at an injection site. Mild stomach upset starting an NSAID. Drowsiness in the first weeks of gabapentin.

Call the team

Fever with a new or worsening infection while on a biologic or JAK inhibitor. Persistent vomiting. Mouth sores that stop your child eating. New rash. Yellowing of eyes or skin. Numbness or tingling in hands or feet. Muscle cramping or spasms after a bisphosphonate infusion, which can mean low calcium. New psoriasis-like rash on a TNF inhibitor.

Go now

Trouble breathing, swelling of the face or throat, or hives during or after an infusion. High fever with lethargy while immunosuppressed. Any new weakness, numbness, or change in walking or bladder and bowel control.

Vaccines

Vaccines are one of the questions families ask most, and the answer depends on whether the vaccine is live. The short version is that routine non-live vaccines are encouraged, and live vaccines are generally held back while a child is on immune-lowering treatment, with a few limited exceptions that only the rheumatology team should decide.

Live and non-live vaccines

Non-live, generally fine

The flu shot, COVID-19, tetanus and whooping cough (DTaP and Tdap), hepatitis A and B, HPV, pneumococcal, meningococcal, inactivated polio, and the recombinant shingles vaccine. Usually recommended and often encouraged, though the response can be somewhat weaker on some medicines.

Live, generally avoided

MMR (measles, mumps, rubella), varicella (chickenpox), the nasal spray flu vaccine (FluMist), rotavirus, yellow fever, and some travel vaccines such as oral typhoid. These contain a weakened version of the germ, which can cause real illness in a child whose immune system is held down.

Flu shot or nasal spray

The injected flu shot is not live. The nasal spray is live. Say "flu shot" when you ask, and avoid the nasal spray unless your rheumatologist says otherwise.

Travel vaccines

Yellow fever is avoided during immunosuppression. Raise travel plans with the rheumatology team months ahead, and make sure the travel clinic knows what your child takes.

What the guidelines say

The European guideline for children with rheumatic diseases (EULAR/PRES, 2021) says live vaccines should generally be avoided in immunosuppressed children, and it counts any dose of a TNF inhibitor or other biologic as immunosuppressive. It allows two limited exceptions. An MMR booster, and the varicella vaccine in a child who has never had chickenpox or the vaccine, can be considered for children on TNF inhibitors, IL-1 or IL-6 inhibitors, or low-dose steroids, once the team has weighed the risks and benefits. It says the nasal flu vaccine should be avoided.

The American College of Rheumatology guideline (2022) conditionally recommends against live vaccines during immunosuppressive treatment. Where one is truly needed, it describes a plan for holding the medicine around the vaccine. For a TNF inhibitor that plan is to hold for one dosing interval before and four weeks after. Both guidelines leave the decision to the treating specialist, because it depends on the drug, the dose, the disease, and the vaccine.

Before starting a medicine

When it can be done safely, teams try to give any needed vaccines, including live ones, a few weeks before treatment starts. The EULAR/PRES guideline suggests two to four weeks, and also says that treatment a child needs should not be delayed just to fit vaccines in. Ask for a review of your child's vaccine record at the first visit.

Everyone else in the household

Siblings and parents should stay up to date with routine vaccines, including MMR and chickenpox, because it protects your child. Two standard precautions are worth confirming with your team, as they come from general vaccine practice rather than the guidelines above. If someone develops a rash after a chickenpox vaccine, keep them away from your child until it clears. After a baby's rotavirus vaccine, careful handwashing, especially after diaper changes, matters for a while afterward.

Telling every clinic

• Say "my child takes [medicine name]" at every vaccine visit, pharmacy, urgent care, and travel clinic. Pediatricians and pharmacies do not always have the rheumatology record.
• Keep the medication list on your phone, and ask the school nurse to have it too.
• If a live vaccine is given by mistake, or you are not sure whether a vaccine is live, call the rheumatology team the same day. The team will tell you what to watch for.

Infections and everyday life

Children on biologics or JAK inhibitors do get more colds, and most are ordinary and handled ordinarily. Standard practice is to notify the rheumatology team about a significant fever or infection, to hold the medication during an active infection if instructed, and to make sure any urgent care or ER doctor knows the child is immunosuppressed. A card or note in your phone with the medication list is more useful than it sounds at 2am.

Fever and illness

Ask your team what temperature, and what other signs, should mean a same-day call for your child, and write it on the medication card. Signs that usually mean calling right away or going to the emergency department include a fever with a child who looks unwell, a fever with new bone pain (infection has to be ruled out), a stiff neck, trouble breathing, a rash that does not fade when pressed, or severe pain.

Holding a dose during an infection

Many teams ask families to hold a biologic or JAK inhibitor during an active infection and restart when it clears, but the rule differs by drug and by infection. Ask for written sick-day instructions for each medicine, and do not stop on your own.

Exposure to chickenpox, shingles, or measles

These can be serious in a child on immune-lowering treatment, especially if the child has not had the disease or the vaccine. Call the rheumatology team the same day you learn of an exposure, even if your child seems fine. For chickenpox there is a preventive treatment, varicella zoster immune globulin (VariZIG), given as soon as possible after exposure, and current US guidance allows it up to 10 days afterward. A similar immune globulin exists for measles. Timing matters, so do not wait for symptoms. It helps to ask the school and any childcare to tell you promptly about chickenpox, shingles, or measles cases.

Screening and everyday precautions

TB and hepatitis screening are done before biologics and JAK inhibitors and repeated periodically, because these drugs can wake up infections that have been quiet. Day to day, handwashing, a yearly flu shot for the child and the household, and staying clear of obviously sick contacts where practical are enough. The aim is not to isolate a child, who should still go to school and take part in normal life. Dental care matters too, since mouth infections can spread. See the dental step above.

• EULAR/PRES vaccination recommendationsAnnals of the Rheumatic Diseases, 2023. For children with rheumatic diseases
• 2022 ACR vaccination guidelineFor patients with rheumatic and musculoskeletal diseases, including hold schedules
• CDC: VariZIG after chickenpox exposurePost-exposure prevention for people with weakened immune systems

Questions to ask about any new medication

• Is this treating the inflammation, the pain, or both?
• How long before we should expect to see a difference?
• What would tell us it is working, and what would tell us it is not?
• What labs are needed and how often?
• Which side effects are expected, and which ones mean I should call you?
• What do we do about vaccines, illness, and surgery while on this?
• For a bone-directed drug: does my child need a dental check first, and is there dental work we should finish before starting?
• How long would my child stay on it, and how would we stop?
• Is there a patient assistance program for this drug?

Three different kinds of not working

They look the same from the outside and they lead to completely different next steps. Naming which one you are in is the most useful thing you can do before a visit.

It never worked

Primary failure. The child was on an adequate dose for an adequate length of time and nothing meaningful changed. This suggests the mechanism is wrong for this child, which usually points toward a different class of drug rather than a different drug in the same class.

It worked and then stopped

Secondary failure, also called loss of response. Something changed, and with biologics it is often that the body has started producing antibodies against the drug or that the child has outgrown the dose. This frequently has a fixable explanation, and switching within the same class often works.

It works but we cannot stay on it

Intolerance. The disease is responding but the side effects are not livable. Here the mechanism is right, so a different drug in the same class, a different route of administration, or a dose adjustment is usually tried before abandoning the approach.

How long before you can judge

Stopping too early is as common a problem as staying too long. These are the rough windows used in consensus guidance and practice. Your rheumatologist may work to different ones for good reasons.

What counts as working

Teams weigh two things that do not always agree: how your child feels and functions, and what the imaging shows. A child can feel much better while lesions persist, or feel no different while a scan improves. Neither one alone settles the question.

This matters at a switch decision because the answer changes depending on which is lagging. Pain that continues after imaging has cleared points toward a pain-directed approach. Imaging that stays active after symptoms resolve usually means staying the course on disease treatment rather than declaring victory. Ask directly which of the two is driving the recommendation.

How disease activity gets measured

CNO has no single agreed measure of disease activity, and that gap is openly acknowledged in the consensus literature. It is part of why families so often feel the assessment is subjective. Several instruments do exist, and knowing their names changes the conversation you can have.

CDAS

The CNO Clinical Disease Activity Score. Developed by the CARRA CNO workgroup and validated in 2023. It has three parts, summed into one number: your child's pain on a 0 to 10 scale, a patient or parent global assessment of disease activity on a 0 to 10 scale, and the count of clinically active lesions, meaning bones that are tender, swollen, or warm on examination. It needs no imaging.

PedCNO score

An older composite response measure combining imaging findings, inflammatory markers, and physician and family assessments. Used mostly in research, and reported as PedCNO30, 50, or 70 to describe the degree of improvement, similar to how response is reported in juvenile arthritis trials.

CHAQ

The Childhood Health Assessment Questionnaire. A general function questionnaire borrowed from juvenile arthritis. Measures what a child can actually do rather than how much disease is present.

MRI scoring tools

Standardized ways of counting and grading lesions on whole-body MRI, including a CNO-specific MRI scoring tool and a radiologic index. These show good agreement between radiologists, which matters when scans are read at different centers over years.

Newer work suggests the best assessment combines both sides rather than picking one: composite scoring that pairs clinical data with MRI lesion counts outperformed any single measure at capturing disease activity. That is the direction the field is moving, and it is the reason your team is likely to keep scanning even when your child feels well.

You do not need a clinic to keep a version of this. A pain rating and a one-line note on how active things seem, recorded consistently, turns "she seems worse lately" into something a rheumatologist can act on. It also produces exactly the dated record that strengthens an insurance appeal. Ask your team whether they use CDAS or any other measure, and whether they want your numbers between visits.

Switch or swap

Rheumatology borrows this framing from inflammatory bowel disease and rheumatoid arthritis, where it is much better studied than in CNO. It is still the reasoning most clinicians use.

What actually gets combined

Escalation in CNO is partly sequential and partly additive, and the two get confused easily, including in the clinic room. Some treatments replace each other. Others stack. These are the combinations that are established:

What does not get combined is just as useful to know. Two TNF inhibitors are never given together. Moving from adalimumab or etanercept to infliximab is a switch, not an addition, even when it gets described as "adding" the new one. Stacking drugs that hit the same target multiplies infection risk without adding benefit. Combining two different biologics is likewise uncommon and confined to expert centers.

When the spine is involved and it is still progressing

This is a specific and fairly common situation: a child on a TNF inhibitor with methotrexate, with new or worsening vertebral disease. The options a team weighs, roughly in the order they tend to come up:

• Add a bisphosphonate to what is already running. This is the consensus-supported move for vertebral involvement with structural damage, and it is genuinely additive rather than a replacement.
• Switch within the TNF class, commonly to infliximab, which is given intravenously, can be dose-escalated, and allows drug levels and antibodies to be measured. If the current biologic faded after working well, this often restores control.
• Check drug levels and antibodies first, where available, since a low level with high antibodies points to a switch while an adequate level with no antibodies suggests the mechanism itself is not enough.
• Change class, to a JAK inhibitor or IL-1, IL-6, IL-17 or IL-23 blockade, if the disease never responded to TNF blockade at all.

Jaw lesions alongside spinal disease are worth naming explicitly to the team, since mandibular involvement carries its own dental consequences and factors into the bisphosphonate conversation, where a dental check comes before starting.

What the numbers actually look like

Published cohorts give a realistic picture of how often treatment changes. In one long-term study of children with CNO, all patients started on NSAIDs and by three months about 23 percent had reached complete remission while most of the rest had partial improvement. Around 45 percent went on to need second-line therapy. Of those who got there, bisphosphonates and TNF inhibitors both performed well, with roughly 70 percent of children on a TNF inhibitor showing a favorable outcome and most of the pamidronate group reaching complete remission by six months. Corticosteroids produced early improvement but nearly half relapsed within a year, which is why they are used as a bridge rather than a plan.

Figures from a single-center long-term outcomes study and reported in review literature. Cohorts differ in size, era, and how remission was defined, so treat these as the shape of the disease rather than a prediction for any one child.

Relapse after stopping

Relapse is common and it is not a treatment failure. Half of patients in that cohort relapsed at a median of around two and a half years, and only about 40 percent were still relapse-free at five years. This is why tapering tends to be deliberate and guided by imaging as well as symptoms, and why German consensus recommendations suggest following patients for at least three years after medication-free remission.

Practically: a return of pain in a previously affected site after stopping treatment is worth reporting promptly rather than waiting for the next scheduled visit. Restarting something that already worked is usually straightforward.

When several things have failed

A small number of children go through multiple treatments without durable control. At that point the useful moves are:

• A second opinion at a center that sees CNO regularly, if you have not had one
• Revisiting the diagnosis, since a few conditions mimic CNO and a small subset of cases are driven by a single gene that changes treatment entirely
• Asking whether genetic testing is indicated, particularly with very early onset or unusual features
• Asking about IL-1, IL-6, IL-17 or IL-23 blockade and JAK inhibitors, which are where refractory disease generally goes
• Asking about combination therapy rather than another single-agent switch
• Enrolling in CHOIR or the CARRA registry, and asking whether any trial fits
• Bringing in pain management and pain psychology alongside disease treatment, not instead of it

Questions to ask at a switch decision

• Which kind of failure do you think this is: it never worked, it stopped working, or we cannot tolerate it?
• Are we switching because of symptoms, because of imaging, or both?
• Is there a drug level or antibody test that would tell us why this stopped working?
• Are we changing mechanism or staying in the same class, and why that choice?
• Should we add something to what we are on rather than replace it?
• How long will we give the new treatment before we judge it?
• What happens to the current medication: stop, taper, or overlap?
• If this one does not work, what is the next option after it?

That last question is worth asking every time. Knowing there is a plan behind the current plan changes how a family experiences the wait.

504 plans

A Section 504 plan is a formal document requiring the school to accommodate a student whose health condition substantially limits a major life activity. Pain and mobility limits during flares often meet that threshold, though the school conducts its own evaluation. A 504 differs from an IEP: a 504 provides accommodations within general education, while an IEP provides specialized instruction. Most children with CNO need a 504 rather than an IEP unless there is a separate reason for specialized instruction.

You can request a 504 evaluation in writing at any time, and schools are required to respond to written requests. Once a plan exists, you can request written amendments to add accommodations as needs change.

Accommodations worth requesting

• Elevator access instead of stairs during flares
• A second set of textbooks kept at home, so there is no heavy backpack
• Extended time on tests and assignments during active flares
• A flexible attendance policy for appointments, infusions, and high-pain days
• Modified or excused physical education during flares, written so it does not default to sitting out entirely
• Permission to stand, stretch, or change position without asking
• Home or remote instruction during hospitalizations or prolonged flares
• Access to the nurse's office, and authorization for scheduled medications
• Seating near the exit, and extra time between classes
• A rest period or a quiet place to go, written in for fatigue rather than only for pain
• A reduced or prioritized homework load during active disease, so the evening is not spent recovering the school day
• A plan for makeup work that does not punish medically excused absence

Making it stick

A letter on clinic letterhead from your rheumatologist carries real weight in a school meeting. Ask for one that names the diagnosis, describes that symptoms fluctuate unpredictably, and lists the specific accommodations recommended. Bring it to the meeting rather than mailing it in advance. Put requests in writing by email so there is a record, and ask for the agreed plan in writing afterward.

Talking to teachers

A short written explanation to the school nurse and homeroom teacher at the start of each year is worth more than a long one. Three points cover it: what CNO is in one sentence, that your child may look completely well on a day they are in significant pain, and who to contact. Teachers are generally cooperative once they understand it is not behavioral and not a choice.

Activity

During a flare

Activity guided by pain tolerance. Avoid high-impact loading over affected bones, especially weight-bearing bones and the spine. Rest is appropriate, but complete immobility tends to make pain and deconditioning worse.

In remission

Most children can participate normally. Regular low-impact movement is generally encouraged and helps with pain, mood, and bone health.

Contact and high-impact sport

An individual decision with your rheumatologist, and a stricter one with spinal involvement or a fracture history. Get the answer specific to your child rather than from a general rule.

Pain at home

Beyond scheduled medication, the things families find genuinely useful are heat and ice, physical therapy from someone willing to work within pain limits rather than pushing through them, protected sleep, and pacing so that a good day does not get spent entirely and paid for over the next three. Pediatric pain psychology is not about telling a child the pain is in their head. It teaches concrete skills for living with a body that hurts, and it is one of the better-evidenced interventions in chronic pediatric pain. Ask for a referral if pain is affecting mood, sleep, or school attendance. If pain keeps getting in the way, managing pain covers pain clinics and therapy.

Getting through a flare

Flares are the rhythm of this disease, and most of managing CNO happens at home rather than in a clinic. Having a plan written down before you need it is worth more than deciding in the moment at eleven at night.

Telling a flare from a bad day

Not every bad day is a flare, and treating each one as a crisis is exhausting for everyone. The things that point toward a genuine flare rather than a rough patch:

• Pain in a known lesion site that has been building over days rather than appearing after an obvious activity
• Pain that wakes your child at night or is present on waking
• A return of fatigue alongside the pain
• New swelling, warmth, or tenderness over a bone
• Loss of function: limping, not using an arm, avoiding stairs, dropping activities they normally want to do
• Pain in a new site with the same character as their usual lesions

A single sore evening after a long day is usually just that. Three days of escalating pain with fatigue is worth a call.

A written flare plan

Ask your rheumatology team to help you put one together. It is a short document and it answers, in advance, the questions you will not want to be working out under pressure:

• What to do first at home, including whether there is a rescue or as-needed medication and how to use it
• Whether and how to adjust the scheduled medication, which is a question only your team can answer
• How many days of worsening before you call rather than wait
• Who to call, and what the after-hours route is
• What would prompt new imaging
• The specific symptoms that mean go to an emergency department rather than call
• What to tell the school, and who sends that message

At home during a flare

Heat over the affected area helps many children, ice helps others, and it is worth finding out which. Keep the scheduled anti-inflammatory going rather than switching to as-needed dosing, since NSAIDs work continuously. Protect sleep, because pain and fatigue both worsen with poor sleep and it becomes self-reinforcing. Reduce loading on the affected bone without going to complete rest, since total immobility tends to make both pain and deconditioning worse. Pace the good days so that one good afternoon does not cost the next three.

Rules can loosen during a flare. More couch time, more screen time, easier food, fewer chores. That is a reasonable trade, not a failure of parenting, and most families find the ordinary expectations come back on their own when the flare settles.

Track it while it is happening

A flare is exactly when a record is most valuable and least likely to get made. A daily pain number, what was taken, and what your child could not do that day is enough. Three months later that record is what lets a rheumatologist see a pattern, and it is the evidence an insurance appeal runs on. Reconstructing it from memory at the next visit does not work.

Quality of life, and the part nobody warns you about

Quality of life in CNO is significantly reduced, comparable to what is seen in other chronic rheumatic diseases. That finding is worth stating plainly because families often conclude they are handling it badly, when in fact the disease has a well-documented weight to it.

What that looks like day to day is missed school, dropped sport, friendships that thin out during long flares, and the particular grief of a child who identified as an athlete and cannot be one this season. Those losses are real and they are not solved by better pain control alone. Pediatric pain psychology, school support, and finding a modified version of the thing they loved all help more than waiting for the disease to resolve.

Watch for anxiety around scans and appointments, low mood during long flares, and a child who stops mentioning pain because they have learned it changes nothing. Any of those is a reason to ask the rheumatology team for a referral, and asking early is better than asking once it is entrenched. The emotional health section covers who can help and how to ask.

Siblings

Siblings notice everything and usually say nothing. Time that is theirs alone, and an age-appropriate explanation of what is happening, prevents a lot of later resentment. The Sibling Support Project has resources built specifically for this.

Start by working out which pain it is

Children with CNO can have more than one kind of pain at once, and the right response is different for each. Your rheumatology team is the one to sort this out, and it helps to ask the question directly.

Inflammatory pain

Comes from active bone inflammation. Treated by controlling the disease, which is what the medication sections cover. Pain tools help, but they do not replace treatment, and pain that is getting worse can mean the disease is not controlled.

Structural pain

Comes from damage, such as a vertebral fracture, a growth disturbance, or a limb length difference. Needs orthopedic or spine input as well as pain care.

Amplified pain

After months or years of hurting, the nervous system can turn the volume up, so pain continues or spreads even when inflammation is controlled. Also called central sensitization. The pain is real. It responds to a pain-directed approach rather than to more immunosuppression.

Clues that amplified pain is part of the picture include pain that continues after imaging has cleared, pain that spreads beyond the known lesions, and pain that is much worse on bad days, anxious days, and tired days. None of these proves it, and many children have a mix. The section on treatment that is not working explains why this matters at a switch decision.

The toolkit beyond disease treatment

Medicines for pain

NSAIDs and acetaminophen first, and sometimes nerve-pain medicines such as gabapentin, pregabalin, amitriptyline, or duloxetine at pain-modifying doses. Details are in the medication reference. Opioids have no good evidence for long-term pain in children and carry real risks, so ask the team before one is used outside a short-term situation such as a fracture or surgery.

Heat, cold, and positioning

Simple, safe, and useful during a bad stretch. Warmth before activity for stiffness, cold after a sore day, and a supportive position at night. See pain at home in the daily life section.

Physical therapy

Gentle strengthening, flexibility, gait and posture work, and a gradual return to activity after a flare. Needs clearance from the rheumatology team when the spine or a weight-bearing bone is involved. Adherence is the hard part, because activity can hurt at first.

Occupational therapy

Practical changes for school and home, such as a lighter bag, seating, handwriting, and pacing a day. There are no pediatric trials, but the practical value is clear to families who use it.

Psychological pain skills

Cognitive behavioral therapy, acceptance and commitment therapy, relaxation and breathing, guided imagery or hypnosis, mindfulness, and biofeedback. These teach a child to change how pain and attention interact. Described in more detail below.

Massage, yoga, and acupuncture

Preliminary evidence of benefit for pain, stiffness, and distress, and generally low risk. Ask the team first, especially during treatment that lowers immunity, and avoid anything that loads a spine with known lesions.

Sleep

Pain disrupts sleep and poor sleep amplifies pain. Worth raising at appointments in its own right. See the emotional health section.

What pain psychology looks like in practice

It is not a lecture that the pain is in the head. A pain psychologist usually starts by listening to the pain story, then explains how pain works and why it can persist after inflammation has settled. From there the work is practical:

• Skills for calming the body during a pain spike, such as slow breathing, relaxation, and imagery
• Attention and thought patterns that make pain louder, and what to do instead
• Gradual activity that builds up steadily rather than the boom and bust of overdoing a good day and crashing for three
• Goals built around function, such as a full school day, a night of sleep, or an hour of the sport they love, rather than a pain number alone
• Parent coaching on how to respond to pain in ways that help a child cope
• A plan for flares that the child, parents, and school share

It usually runs as a series of sessions over weeks to months. Many hospitals offer it through the rheumatology clinic or a pain clinic, and telehealth works well for most of it.

Pain clinics and intensive programs

A pediatric pain clinic brings together a pain physician, a psychologist, a physical therapist, and nurses, and often treats a child with a plan that covers all of these at once. Your rheumatology team can refer. Some centers also run intensive interdisciplinary pain treatment, which is a full-day or live-in program lasting several weeks with daily physical therapy, occupational therapy, and psychological work, aimed at children whose pain is disabling.

These programs are not for pain that is mainly driven by active disease. They are for pain that continues, and that limits school, sleep, and normal life despite good disease control. Places are limited, waiting lists are common, and some families travel. Insurance may require prior authorization, so involve the rheumatology team and the program's financial coordinator early.

Reasons to ask for a pain referral

• Pain that keeps interfering with school, sleep, or activity even though scans and bloodwork look better
• Pain that has spread or changed pattern without new lesions on imaging
• A child who has stopped doing things they used to do because of pain or fear of pain
• Medicine side effects that are limiting pain control, such as drowsiness or brain fog
• Pain that is steadily taking over family life

What parents can do

• Believe the pain. Children with a rare disease often learn that adults doubt them. Saying "I believe you" matters.
• Stay calm and steady. Children read a parent's face. A calm, matter-of-fact response helps a child settle more than reassurance repeated over and over.
• Keep routines going where the disease allows: school, meals, bedtime, friends. The aim is a life with pain in it, not a life organized around it.
• Notice effort, not only pain scores. Praise the child for using a skill, attending, or trying something hard.
• Avoid asking about pain constantly. Checking in all day keeps attention on it. Agree a regular time instead and let the rest of the day be about other things.
• Ask the pain team how to respond. Research in pediatric pain suggests that very protective responses, however loving, can sometimes increase disability, so parent coaching is a standard part of good programs. This is not blame, and it is easy to do.

Keep the pain and function record described in the daily life section. It is useful to both teams.

What to expect

The aim is usually less pain, fewer bad days, and a child who is doing more, not zero pain. Progress tends to be gradual and uneven, and a flare will set it back for a while. If nothing has changed after a few months of a plan that the child is following, ask the team to review it rather than concluding that nothing helps.

How strong is the evidence

Most pediatric pain research is in other conditions, such as juvenile arthritis, fibromyalgia, and general chronic musculoskeletal pain. Almost none was done in CNO.

Questions to ask the pain team

• Have you treated children with a rare inflammatory bone disease, and will you coordinate with our rheumatologist?
• How will you decide how much activity is right when the disease is active?
• What will the first few sessions involve, and what should we practice at home?
• What are we aiming for, and how will we measure it?
• When would you consider an intensive program, and what is the waiting time?
• What should we do on a bad day, and when should we call the rheumatology team instead?

Sources

• Evidence-based interdisciplinary treatment for pediatric musculoskeletal painReview of drug, psychological, physical, and complementary treatments
• Intensive interdisciplinary pain treatment of children: systematic reviewOne randomized trial and nine non-randomized studies
• Psychological therapies for chronic pain in children and adolescentsCochrane review
• Online self-management program for teens with juvenile arthritisRandomized trial, 289 adolescents

Why this comes up so often

Families in the community describe the same things again and again: dread of scans after a bad experience, worry about what the future looks like when the body is unpredictable, and the weight of treatment that goes on for years. Many say a psychologist made a real difference, and some say every child with CNO should be offered one.

The research is thinner than the experience. No large study has measured anxiety or depression specifically in children with CNO. What exists points in one direction, and it comes from groups that are close to CNO but not the same.

Sources are listed at the end of this section. Only the first figure is from children with CNO, and it is a small study. The other two are reasons to ask, not predictions for your child.

Signs it is time to ask for help

• Dread or avoidance of scans, needles, infusions, or appointments, including stomach aches or panic the day before
• A scan that could not be completed, or a pattern of attempts that go worse each time
• Low mood, irritability, or flatness that lasts two weeks or more, or that is not easing as a flare settles
• Pulling away from friends, activities they used to like, or school
• Sleep changes, either trouble falling asleep or sleeping far more than usual
• A child who stops mentioning pain because they have learned it changes nothing
• Pain that continues after scans and bloodwork look better, or that is clearly worse on bad days and anxious days
• Strain on the family, such as a parent who is not coping or a sibling who is acting out

Any one of these is a reason to ask the rheumatology team for a referral. Asking early is easier than asking once the pattern is set.

Who does what

The titles are confusing and the roles overlap. In practice, start with whoever your rheumatology team recommends.

Pediatric psychologist

Talk therapy and skills for children with medical conditions: coping with pain, fear of scans and needles, sleep, adjusting to a long illness. Often sits inside the rheumatology clinic, a pain clinic, or a hospital program sometimes called a medical coping clinic. Does not usually prescribe.

Child and adolescent psychiatrist

A physician who diagnoses and treats anxiety, depression, and other mental health conditions, and who can prescribe. Worth involving when symptoms are severe, when medication is being considered, or when therapy alone is not enough.

Therapist, counselor, or social worker

Ongoing counseling in the community or through the hospital. Look for someone with experience in chronic illness. Hospital social workers also help with school, insurance, and finding local providers.

Child life specialist

Not a therapist, but the first stop for scan and procedure fear. Prepares children with mock scanners, practice, and distraction. See the diagnosis section on preparing for an MRI.

School counselor or psychologist

Support during the school day, and a route to the accommodations in a 504 plan. Free through the school.

Pediatrician

A good first screening point and a referral source, especially when the rheumatology clinic has no psychology service.

What the support actually involves

Common approaches include cognitive behavioral therapy, acceptance and commitment therapy, relaxation and breathing skills, biofeedback, sleep strategies, and gradual practice with the thing a child fears, such as lying in a scanner. Good programs also coach parents, because how a parent responds to pain and fear shapes how a child copes.

How strong is the evidence

A Cochrane review of psychological therapies for children and teens with chronic pain found they reduced pain at the end of treatment and reduced disability, with the disability benefit lasting about a year in children with mixed pain conditions. The pain benefit often did not last, and the reviewers rated the evidence low or very low quality. No trial has been done in CNO specifically. So the honest summary is that it is a reasonable, low-risk thing to try, with modest and unproven benefit for pain, and with clear value for fear, sleep, and coping that families describe firsthand. The managing pain section covers pain clinics, physical therapy, and the wider evidence.

Fear of scans and procedures

Children with CNO have imaging for years, so a fear that is built now is one that gets repeated many times. After a failed scan attempt, the best next step is usually preparation rather than another try. Ask for a child life specialist and a mock scanner session. One children's hospital reported that about two thirds of the children who used a mock scanner went on to have an unsedated scan, including some as young as five or six.

• Ask for a psychology referral if dread persists after preparation, or after more than one failed attempt
• Ask whether a gradual exposure plan is possible, working up from a scanner sound recording to lying on the table
• Sedation or anesthesia is a legitimate option when repeated attempts are distressing. Many teams prefer one good scan to several traumatic ones, and it is reasonable to ask for it
• Ask about numbing cream, a parent in the room, headphones, and a familiar routine for needle procedures

Medicines and mood

Some of the medicines used for CNO can affect mood or sleep, and this is worth knowing before it happens.

• Corticosteroids such as prednisone commonly cause irritability, mood swings, and trouble sleeping, usually easing as the dose comes down.
• Pain-directed medicines such as gabapentin, pregabalin, and amitriptyline can cause drowsiness, brain fog, and mood changes.
• Tell the rheumatology team promptly about any new mood change after a medication starts. Do not stop a medicine on your own.
• If a psychiatrist or other prescriber adds a medicine, give them the full list of rheumatology medicines first and ask the pharmacist to check for interactions.

Sleep, pain, and mood feed each other

Poor sleep makes pain feel worse and mood lower, and pain disrupts sleep. In the small Israeli study, children with poor sleep had lower quality of life and higher inflammation markers. Mention sleep at appointments the same way you mention pain, because treating it is one of the more practical ways to help a child feel better day to day.

Teenagers

Teens often say more to a clinician alone than in front of a parent. Many clinics routinely see older children on their own for part of the visit, and it is worth asking for that. A teen who chooses a therapist, rather than being handed one, is more likely to stay with it. The same skills help later when they take over their own care in the move to adult services.

Parents and siblings

Parents carry the logistics, the worry, and often the fear of the next flare. Your own support is not separate from your child's. A parent who is coping well is one of the most protective things a child with a chronic illness has. See a therapist yourself if you need to, talk to other families, and tell the care team when you are running low. Siblings are covered in the section on daily life.

How to get started

What to say at the next appointment

"We are struggling with [scans, pain, mood, sleep]. Can you refer us to psychology, or to the pain clinic's psychologist? Do you have a coping program for children with chronic conditions?" That is enough. You do not need a diagnosis or a crisis to ask.

Finding someone

• Ask the rheumatology team first. Many hospitals have psychologists embedded in rheumatology or pain clinics, and a referral from inside the hospital is usually the fastest route.
• Ask the hospital social worker for local therapists who know chronic illness.
• Search directories by "chronic illness," "medical trauma," or "pediatric health psychology," and look for someone who will coordinate with the rheumatology team.
• Telehealth widens the choice a great deal for rural families and for times when a child is too sore to travel.

Questions to ask a therapist before starting

• Have you worked with children who have chronic pain or a chronic medical condition?
• What approach do you use, and how will we know whether it is helping?
• Will you work with the rheumatology team, with our permission?
• How are parents involved, and will my teen have time alone with you?
• How many sessions should we expect, and what will it cost?

Cost and coverage

Mental health services are often covered under a separate behavioral health benefit with its own network, so check that before booking. Services inside a hospital program are sometimes billed as medical care, which can change what you pay, so ask the billing office. School services are free. Medicaid and CHIP generally cover mental health care for children. If you have no coverage or a high balance, the hospital financial assistance policy may apply to hospital-based psychology as well. See the insurance section for how to ask.

Sources

• CNO in children: sleep, pain, quality of life and disease activityJournal of Rheumatology, 2024. Thirty-six children, five Israeli centers
• Quality of life in adults with SAPHO syndrome and CNO138 adults. The source of the anxiety and depression figure
• Anxiety and depressive symptoms in juvenile arthritisJournal of Rheumatology, 2022. Related condition, not CNO
• Psychological therapies for chronic pain in children and adolescentsCochrane review. Source of the evidence summary above
• Mock MRI scanners to reduce anesthesia useNationwide Children's Hospital. A single-center report
• 988 Suicide and Crisis LifelineUnited States. Call or text 988

Why the denials happen

A prior authorization system checks whether a drug is approved for the diagnosis on the claim. For CNO the answer is always no, because nothing is approved for CNO. The first denial is usually automatic and says nothing about the merits. Treat it as the start of the process rather than a verdict.

What a strong appeal contains

• A letter of medical necessity from your rheumatologist, naming this specific child and this specific drug
• Documentation of what was tried before and why it failed, which satisfies step therapy requirements
• Imaging reports showing active, multifocal, or vertebral disease
• Published literature supporting the treatment in CNO, including the CARRA consensus treatment plans
• A clear statement that undertreated CNO carries a risk of permanent skeletal damage
• Your own symptom and function records, which document the day to day impact no clinic note captures

Keep a call log

Every insurance call: date, time, the representative's name, the reference number, and what was said. It takes thirty seconds and it is what makes an external review possible. If a representative tells you something that turns out to be wrong, that log is your evidence.

Levels of appeal

Peer to peer

Your rheumatologist speaks directly with the insurer's reviewing physician. Often the fastest route and frequently successful. Ask for it explicitly.

Internal appeal

A formal written appeal to the insurer. There are deadlines, usually stated in the denial letter. Meet them.

External review

An independent reviewer outside the insurance company. Available in most plans after internal appeals are exhausted, and this is where documentation quality decides outcomes.

Expedited appeal

Available when a delay would seriously jeopardize health. Worth requesting where there is active spinal disease.

Cost assistance

Manufacturers of biologics run copay cards and patient assistance programs that can bring out-of-pocket cost to nearly nothing for commercially insured families. Your rheumatology practice's care coordinator usually knows which program applies and can start the paperwork. Note that copay cards generally cannot be used with government insurance, where foundation grants are the alternative route.

Medicaid pathways

Even when family income is above the standard Medicaid limit, a child with a significant chronic condition may qualify through the Katie Beckett or TEFRA waiver, which bases eligibility on the child's own income rather than the family's. Availability and names vary by state. The social worker at your pediatric rheumatology center is the right first call.

If you have no insurance, or buy your own

This section is written for the United States. Everything above assumes a family with a plan to appeal against. Some families have no coverage, have just lost it, or buy an individual plan, and the options are different. The most important thing is the same in every case: tell your rheumatology team about the cost problem early. Their social worker or financial counselor handles this every week, and a plan can often be adjusted around cost, but only if they know.

Check Medicaid and CHIP first, for the child alone

Children qualify at much higher household incomes than adults do, and the limits vary by state. Medicaid and CHIP take applications all year, with no enrollment window. Apply for the child even if the parents do not qualify or are covered somewhere else. The Katie Beckett or TEFRA route above is also worth asking about when income is too high for standard eligibility.

Buying an individual or Marketplace plan

Losing other coverage opens a special enrollment period, generally 60 days before or after the loss, and 90 days after losing Medicaid or CHIP. Outside of that, enrollment is limited to the yearly open enrollment window. Marketplace plans cannot exclude a child because of a pre-existing condition, and they carry the same internal and external appeal rights described above. Before choosing a plan, check these four things, because they matter more for CNO than the monthly premium:

• Whether your child's pediatric rheumatology center is in network, not just the hospital's name
• Whether the infusion site you would actually use is in network
• Which formulary tier the biologics and bone-directed infusions sit on, and whether specialty drugs carry a separate deductible or coinsurance
• The out-of-pocket maximum, since a year with biologics and infusions will likely reach it

Hospital financial assistance, sometimes called charity care

Most nonprofit hospitals in the US are required by federal tax rules to have a written financial assistance policy. It must say who is eligible, whether the help is free or discounted care, and how to apply. Your child's hospital will have one even if no one has mentioned it, and the policy is usually posted on the hospital's website. Eligibility is often based on household income compared with the federal poverty level, and the details differ a lot from one hospital to the next.

• Ask the billing office or a patient financial counselor for the "financial assistance" or "charity care" application. Use those exact words.
• Apply as early as you can, ideally before a bill goes to collections. Many policies also cover care you have already received, though deadlines vary, so ask.
• Check which providers the policy covers. The hospital's facility charges are usually covered, while a separate physician group or radiology practice may bill under different rules.
• Some hospitals apply it to insured families with large balances after the deductible. It is worth asking even if you have a plan.
• If you are uninsured, ask for a written estimate before scheduled care such as an MRI or infusion. In the US, self-pay patients are entitled to a good faith estimate for scheduled services.

Free medication from the manufacturer

Manufacturers of the major biologics run programs that supply medicine at no cost to patients with no prescription coverage and limited income. This includes the makers of adalimumab (Humira), etanercept (Enbrel), certolizumab (Cimzia), and the Janssen products (infliximab and golimumab). They generally ask for proof of income, a statement of insurance status, and a signature from the prescriber, so the clinic is part of the application. The programs change often. Ask your care coordinator which one applies to your child's exact drug, because they usually have a working relationship with the program and know the current rules. Copay cards are a different thing, and they do not work for families on government insurance.

These programs cover the drug, not the infusion visit or the monitoring labs. For infused drugs, the hospital financial assistance route above is what covers the rest.

• Special enrollment periodshealthcare.gov
• Medicaid and CHIPhealthcare.gov
• Hospital financial assistance policy rulesirs.gov
• Prescription assistance programsSpondylitis Association of America

Infusion site of care

For pamidronate or infliximab, where the infusion happens changes what you pay. Hospital outpatient, freestanding infusion center, and in-office administration are billed differently and can differ by thousands of dollars for the same drug. Call before the first infusion and confirm site-of-care coverage and cost sharing in writing.

• NORD Medicaid eligibility by staterarediseases.org
• Patient Advocate FoundationCase management and co-pay relief
• NeedyMedsAssistance program database

Why other families are worth finding

Other CNO parents have been through the diagnostic limbo, the insurance denials, the 504 meeting where nobody had heard of the disease, and the wait for MRI results. The practical knowledge in those groups exists nowhere else, and it is specific in a way that no clinic handout can be.

The caution that goes with that: not every group is well moderated, and confident advice from a stranger is still advice from a stranger. Medical information from a group is a good prompt for a question to your rheumatology team, not a substitute for the answer.

Registries and research

CARRA

The Childhood Arthritis and Rheumatology Research Alliance. The organizing body for pediatric rheumatology research in North America, and the source of the CNO consensus treatment plans. Its registry is the primary pediatric rheumatic disease registry in the region.

CHOIR

The Chronic nonbacterial Osteomyelitis International Registry, established by the CARRA CNO and CRMO workgroup and led from Seattle Children's, focused specifically on this disease. Ask your rheumatologist whether your center participates.

Clinical trials

Search ClinicalTrials.gov for CNO and CRMO. Trials in rare pediatric disease enroll slowly, so joining a registry is often the higher-yield contribution.

Enrolling in a registry is usually straightforward and takes place through your treating center. Since CNO has no approved therapies, the case for any future approval will be built out of exactly this kind of data.

Why trials matter here specifically

The field has essentially no randomized evidence. A recent systematic review of pediatric CNO treatment found no randomized controlled trials at all, and the published calls for trials have become pointed. That absence is the direct reason no drug has ever been approved for this disease, which in turn is the reason every family fights the same insurance battle.

Two things changed recently that make trials more feasible: the 2025 EULAR/ACR classification criteria give an agreed definition of who belongs in a study, and the validated CDAS gives an agreed way to measure whether anything worked. Registries supply the natural history data that trials are designed against. If you have ever wondered whether enrolling is worth the paperwork, that is the chain it feeds.

Moving to adult care

CNO can persist into adulthood, and the handoff is a known weak point. Start the conversation well before your child turns eighteen rather than in the final year.

• Ask your pediatric team at what age they transition patients and whether they have an adult rheumatologist they refer to
• Ask for a written transition summary: diagnosis, imaging history, every treatment tried with dates and outcomes, and current plan
• Collect the actual imaging, not just the reports, since an adult center will want to compare
• Bring the adult consensus recommendations to the first adult appointment if the new rheumatologist has not treated CNO
• Make sure your child knows their own history, medication names, and what to say in an emergency department before they are managing it alone
• Check insurance implications, since coverage under a parent's plan and eligibility for assistance programs both change

Where families gather

Facebook hosts the largest CNO and CRMO communities, including a long-running group for families and a separate one for adult patients. Ask your rheumatology team or an established organization for a current recommendation rather than joining the first group a search returns.

• NORD rare disease databaseClinician-reviewed disease overview
• NIH GARDGenetic and rare diseases information
• CARRAResearch alliance and consensus treatment plans
• CARRA registries and CHOIRHow to enroll
• Seattle Children's CRMO programA dedicated multidisciplinary CNO clinic, leads the CHOIR registry, and publishes a family web app covering home management, MRI preparation, and school
• CRMO AwarenessFamily-founded advocacy organization
• ClinicalTrials.govOpen studies in CRMO and CNO
• Sibling Support ProjectFor brothers and sisters
• Global Genes RARE ListRare disease advocacy and family resources

Adults with CNO

Adults with this disease are underserved in a way that is hard to overstate. Fewer specialists see it, referral routes are unclear, and much of the published research is pediatric. The 2025 international consensus recommendations for adult CNO are the most useful single document to bring to an adult rheumatologist who is unfamiliar with the disease. Adults also transition into this from pediatric care, which is why transition planning belongs in the conversation well before a child turns eighteen.

Autoinflammatory

Driven by the innate immune system switching on inappropriately. Distinct from autoimmune, where the adaptive immune system makes antibodies against the body's own tissue. CNO is autoinflammatory.

Bone marrow edema

Fluid and inflammation inside bone, the finding that marks an active CNO lesion on MRI. Bright on fluid-sensitive sequences.

Lesion

An area of bone affected by the disease. Lesions can be active, healing, or burnt out, and a child can have several in different states at once.

Flare

A period of increased disease activity and symptoms. Flares and remissions are the characteristic rhythm of CNO.

Multifocal

Affecting more than one site in the skeleton.

Metaphysis

The flared part of a long bone near the growth plate. A favored site for CNO lesions, which is why growth is monitored.

Sclerosis and hyperostosis

Increased bone density and bone overgrowth, both of which can follow chronic inflammation and show on imaging.

Vertebral involvement

CNO lesions in the spine. Present in more than a quarter of patients, often without symptoms, and the finding that most changes treatment.

Vertebra plana

A vertebral body that has collapsed to a flattened shape. One of the structural complications spinal treatment is meant to prevent.

Whole-body MRI (WB-MRI)

A screening scan of the entire skeleton. Finds lesions anywhere, including silent ones, at lower resolution than a targeted scan.

Dedicated or targeted MRI

A detailed scan of one region. What you ask for when a specific area hurts or needs close assessment.

STIR

A fluid-sensitive MRI sequence. Inflammation appears bright, which is how active lesions are identified.

ESR and CRP

Blood markers of inflammation. Frequently normal in CNO even during active disease, so normal results do not rule anything out.

HLA-B27

A genetic marker associated with the spondyloarthritis spectrum. It is not a CNO gene and neither diagnoses nor rules out CNO, but it can matter where CNO overlaps with sacroiliitis, enthesitis, or inflammatory arthritis.

Variant of uncertain significance (VUS)

A genetic change for which current evidence is not enough to say whether it causes disease. Not the same as a pathogenic variant, and generally not a diagnosis on its own.

NSAID

Nonsteroidal anti-inflammatory drug. First-line treatment in CNO, given on a schedule for continuous effect.

DMARD

Disease-modifying antirheumatic drug. In CNO this usually means methotrexate, sulfasalazine, or leflunomide.

Biologic

A drug made from living systems that targets one specific immune signal, such as TNF, IL-1, IL-6, or IL-17.

Live vaccine

A vaccine containing a weakened form of the germ, such as MMR, chickenpox, and the nasal spray flu vaccine. Generally avoided during immunosuppressive treatment, with limited exceptions decided by the rheumatologist.

Non-live vaccine

A vaccine that cannot cause the disease it protects against, such as the flu shot, COVID-19, tetanus, and hepatitis vaccines. Also called inactivated. Generally safe and encouraged on biologics.

Bisphosphonate

A drug that inhibits osteoclasts, the cells that break down bone. Pamidronate and zoledronic acid are the ones used in CNO.

Osteoclast

The cell that resorbs bone. Overactive in CNO, which is why bone-directed drugs help.

Acute phase reaction

The flu-like fever and aches that commonly follow a first bisphosphonate infusion. Expected, usually brief, and usually does not repeat.

Off label

Prescribing an approved drug for a condition it was not approved for. Standard practice in rare pediatric disease, and the root of most CNO insurance denials.

Prior authorization

Insurer approval required before a drug is covered. In CNO the first answer is usually no, and appeals usually succeed.

Step therapy

An insurer requirement to try cheaper drugs first. Documenting what failed and why is how it gets satisfied.

Consensus treatment plan

An agreed standardized approach published by a group of specialists, used to reduce variation between centers and make research comparable. CARRA published these for CNO in 2018.

Remission

Disease inactivity. Can be clinical, meaning symptoms have resolved, or radiologic, meaning imaging has cleared. The two do not always arrive together.

Primary failure

A treatment that never worked, despite an adequate dose given for an adequate time. Usually points toward changing to a different class of drug.

Secondary failure

Also called loss of response. A treatment that worked and then stopped. Often has a specific explanation such as anti-drug antibodies or an outgrown dose.

Anti-drug antibodies

Antibodies the body makes against a biologic, which clear the drug before it can work. The usual reason a biologic fades after a good start. Methotrexate alongside a biologic reduces how often this happens.

Trough level

The drug concentration measured just before the next dose. Used with antibody testing to work out whether a biologic stopped working because of dosing or because of antibodies.

Classification criteria

An agreed definition of who counts as having a disease, used to build consistent groups for research and trials. Not the same as diagnostic criteria, and not meant to decide whether an individual child has CNO.

Extraosseous

Outside the bone. Extraosseous involvement in CNO, including lung involvement, is associated with a more severe course.

Osteonecrosis of the jaw

A rare complication of bone-directed drugs in which jaw bone fails to heal, usually after dental surgery. The reason a dental check comes before starting bisphosphonates.

Central sensitization

The nervous system amplifying pain signals after a long period of pain, so that pain continues even when inflammation is controlled. Real pain, but it needs a pain-directed approach rather than more immunosuppression.

CDAS

The CNO Clinical Disease Activity Score. A validated three-part measure summing your child's pain rating, a patient or parent global assessment of disease activity, and the number of clinically active lesions. Two of the three parts come from the family.

PedCNO score

A composite research measure of treatment response in CNO, combining imaging, labs, and physician and family assessments. Reported as PedCNO30, 50, or 70.

CHAQ

The Childhood Health Assessment Questionnaire. Measures physical function rather than disease activity, borrowed from juvenile arthritis.

Taper

Reducing a medication gradually rather than stopping it. Standard in CNO because abrupt stops are associated with relapse, and required for corticosteroids.

Key clinical sources

These are the primary documents behind the treatment guidance in this handbook. They are written for clinicians, not families, but they are worth knowing about. The CARRA plans in particular are the paper to bring to a rheumatologist unfamiliar with CNO, and to attach to an insurance appeal.

• CARRA consensus treatment plans for CNOZhao et al., Arthritis Care & Research, 2018. The three standardized approaches for CNO refractory to NSAIDs or with active spinal lesions
• German pediatric rheumatology society (GKJR) recommendationsDiagnosis, treatment and monitoring of CNO and CRMO, 2026. Includes imaging intervals and guidance on vertebral involvement
• International expert consensus for adult CNOAnnals of the Rheumatic Diseases, 2025. The naming consensus and the adult diagnostic and treatment pathway
• Treatment response and long-term outcomes in children with CNOJournal of Rheumatology. The source of the escalation and relapse figures in section 07
• Validation of the CNO Clinical Disease Activity ScoreJournal of Rheumatology, 2023. The CDAS, developed by the CARRA CNO workgroup
• EULAR/ACR classification criteria for pediatric CNOAnnals of the Rheumatic Diseases, 2025. For research and trials, not for diagnosing an individual child
• Treatment of pediatric CNO: a systematic reviewThe source for the evidence-quality picture in section 04. Found no randomized controlled trials
• Updates in CNO: emerging insights across the age spectrumCurrent Opinion in Rheumatology, 2026. New genetics, disease clusters, and extraosseous involvement
• EULAR/PRES vaccination recommendations for children with rheumatic diseasesAnnals of the Rheumatic Diseases, 2023. The source for the live vaccine guidance in section 06
• ACR vaccination guideline for rheumatic and musculoskeletal diseases2022. Includes medication hold schedules around live vaccines